CJClément Janot

Clément Janot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clément Janot has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Florence Roucher-Boulez

    Hospices Civils de Lyon, LBMMS, Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est , Lyon F-69000

    5 shared publications
  • Delphine Mallet

    Hospices Civils de Lyon, LBMMS, Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est , Lyon F-69000

    2 shared publications
  • Ingrid Plotton

    Centre hospitalier universitaire de Lyon, laboratoire de biochimie et biologie moléculaire, Université Lyon 1

    2 shared publications
  • Yves Morel

    Laboratory of Biochemistry and Molecular Biology, UM Endocrinology and Rare Diseases, Reference Center for Genital Development, Hospices Civils de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France

    2 shared publications
  • Alexandre Janin

    Hospices Civils de Lyon, LBMMS, Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est , Lyon F-69000

    1 shared publication
  • Aloulou Hajer

    Pediatrics Department - Hédi Chaker Sfax Hospital, Tunisia

    1 shared publication

Latest Publications

  • Rare causes of pediatric primary adrenal insufficiency: Data from a large nationwide Tunisian cohort

    by Rania Khalfallah, Fakhri Kallabi, Delphine Mallet, Manel Guirat, Sana Kmiha, Ines Maaloul, Faten Hadj Kacem, Imen Chabchoub, Hajer Aloulou, Clement Janot, et al.

  • A Recurrent Splice Variant Sheds Light on 11β-Hydroxylase Deficiency in a Unique Large Cohort

    by Clément Janot, Delphine Mallet, Alexandre Janin, Jérome Bertherat, Raja Brauner, Frédéric Brioude, Audrey Cartault, Mélanie Daval-Cote, Stéphanie Espiard, Muriel Houang, et al.

    Context: Congenital adrenal hyperplasia can be due to 11β-hydroxylase deficiency (11βOHD). Sporadic reports of 11βOHD are frequent but overviews on molecular landscape in some populations are lacking. Objective: The aim of this research was to compile a genetic landscape from an 11βOHD cohort, and to report a novel yet recurrent splice variant. Methods: An overview of CYP11B1 variants in a cohort of 11βOHD is presented here. The functional effect of NM_000497.4(CYP11B1):c.954 + 148C > G was studied in silico and in vitro, and a genotype-phenotype correlation study (“SPLICYP” study, No. 22_1787) was conducted. Patients with 11βOHD who underwent genetic testing at the biochemistry and molecular biology department were considered for inclusion. A total of 250 patients, diagnosed from 1990 to 2024, underwent CYP11B1 sequencing. Forty-four patients carried a novel deep intronic variant (NM_000497.4(CYP11B1):c.954 + 148C > G). Four were excluded from genotype-phenotype correlation due to missing criteria. Functional validation was performed using a Minigene Reporter Assay. We retrospectively analyzed genetic findings, clinical features of 11βOHD, and hormonal assays. Results: The Minigene study confirmed that c.954 + 148C > G disrupts splicing by activating a cryptic donor site. Patients carrying this variant had significantly lower steroid precursor levels (P < .034) and delayed pubertal onset (P = .005) compared to severe variant carriers. Conclusion: This retrospective study provides genetic data in a wide cohort of 11βOHD, and identifies c.954 + 148C > G as the most recurrent variant in our Caucasian participant recruitment. Screening of deep intronic regions, coupled with functional in vitro tools, must not be overlooked in the strategy to avoid diagnostic failure.


  • First intragenic inversion of CYP11B1 gene causing 11β-hydroxylase deficiency: a molecular diagnosis easily overlooked

    by Clément Janot, Kahina Mohammedi, Delphine Mallet, Kévin Choron, Ingrid Plotton, Jordan Teoli, Asmahane Ladjouze, Florence Roucher-Boulez

    11β-hydroxylase deficiency (11βOHD) is the second most common cause (5%) of congenital adrenal hyperplasia (CAH). The CYP11B1 gene shares 95% of genomic sequence homology with CYP11B2, and therefore Sanger sequencing remains the gold standard. We present a case of 11βOHD due to an intragenic inversion in CYP11B1 that was missed by both the Sanger sequencing and massive parallel sequencing (MPS) methods. The child was born with virilised genitalia at Prader stage 4 and the biological findings showed a hydromineral retention pattern and a pathognomonic increase in steroid precursors suggestive of 11βOHD. Standard trio analysis revealed only one heterozygous pathogenic variation inherited from the father. The study using MPS showed similar outcomes. Careful observation of the alignment BAM files revealed breaks in sequencing depth, incomplete alignments and systematic paradoxical read-pairs orientation. A specifically designed amplification and Sanger protocol confirmed the novel NM_000497.4( CYP11B1 ):c.[892_1121+7 inv;1121+8_1121+9del]; p.(Glu298HisfsTer113) variant at heterozygous state in the proband and his mother, fulfilling the diagnosis. The present case reports the first short intragenic inversion in CAH and illustrates the pitfalls that must always be kept in mind when using sequencing methods. When the phenotype is unequivocal, a thorough investigation of the locus should be carried out with cross-use of different techniques.


  • Open Access

    Letter to the Editor From Janot et al: « Single-Exon Deletions of ZNRF3 Exon 2 Cause Congenital Adrenal Hypoplasia »

    by Clément Janot, Anne Bachelot, Delphine Mallet, Dominique Simon, Pierre Val, Florence Roucher-Boulez

    We read with great interest the article by Amano et al, which addresses single-exon 2 deletions of ZNRF3 as a novel contributor to adrenal hypoplasia (1).


  • Open Access

    Urinary gonadotropin assay on 24-h collections as a tool to detect early central puberty onset in girls: determination of predictive thresholds

    by Clément Janot, Pauline Perrin, Véronique Raverot, Patricia Bretones, René Ecochard, Sarah Malburet-Testori, Marc Nicolino, Zoé Robert, Florence Roucher-Boulez, Carine Villanueva, et al.

    Is the 24-h urinary gonadotropin assay an effective diagnostic tool in central precocious puberty (CPP) in girls? This study is the first to provide 24-h urinary gonadotropin assay data, using an electrochemiluminescent immunoassay (CMIA), and to report its usefulness as a tool for the diagnosis of CPP. Data about the GnRH test in the diagnosis of CPP are variable and there is no consensus regarding its interpretation. The measurement of FSH and LH in urines was previously reported to be an alternative biological tool. This is a retrospective two-cohort study, involving a setting and a validation cohort. A total of 516 girls, included between October 2012 and July 2015, and 632 urinary collections were analyzed in the setting cohort. In the validation cohort, 39 girls were included between January 2021 and May 2023, and 49 urinary collections were analyzed. This study included girls who consulted for an investigation of disturbed growth rate or a clinical suspicion of puberty onset in different medical centres across France (setting cohort). Girls with a suspicion of precocious puberty onset were addressed at the expert centre of paediatric endocrinology of the Groupement Hospitalier Lyon Est (validation cohort). Pelvic ultrasonography was performed and enabled their classification according to clinical and morphologic changes criteria (prepubertal or pubertal groups). The parents collected 24-h urine samples (u24) according to standardized instructions. FSH and LH (urinary or plasmatic) were measured using a current and automated CMIA. The area under the ROC curves for CPP prediction was 0.709 for u24FSH (P < 0.001), 0.767 for u24LH (P < 0.001), and 0.753 for the u24LH/u24FSH ratio (P < 0.001). We retained all possible combinations of the four thresholds in the validation cohort (u24FSH = 1.1 or 2.0 IU/24 h; u24LH = 0.035 or 0.08 IU/24 h). The combination of u24FSH > 1.1 IU/24 h and u24LH > 0.08 IU/24 h had a positive PV of 85.7% and a negative PV of 94.3%, a sensitivity of 85.7% and a specificity of 94.3%, for classifying prepubertal and pubertal girls in this cohort. This is a retrospective study, in which a margin of error remains due to the inherent uncertainty regarding the clinical assessment of pubertal onset. It must be considered that the thresholds can only apply to the used reagents; measurements without extractions using other reagents are likely to show important heterogeneity. The assay performed herein is a simple, non-invasive, and analytically robust technique meeting the criteria for an alternative to the GnRH test which could be used to supplement its lack of sensitivity. No specific funding was used. All authors declared no conflict of interest. In-house #23-5214 registered study.